Ocular Dosing Abstract
The Office of Generic Drugs (OGD) is tasked, among other things, with reviewing sponsor applications for
ocular dosage forms that purport to be bioequivalent to approved formulations for the same drug. Sponsor
companies want to have high confidence that applications they submit for dosage forms thought to be
bioequivalent will receive favorable reviews. Software that embodies mechanistic absorption modeling
(MAM) and physiologically based pharmacokinetics (PBPK) can be a useful tool to reduce the time and
expense involved in determining the likelihood that a new formulation will be bioequivalent to an
approved dosage form for both industry scientists and regulators.
Developing a state-of-the-art capability for ocular MAM/PBPK software requires an extensive knowledge
base to serve as the scientific foundation, talented scientists to apply the knowledge base in the
development of useful equations and logic suitable for software, high-level computer programming skills to
encode the equations and logic into user-friendly software, and experienced scientists to test, validate,
document, and support the software for use by others not involved in its development.
This proposed project will advance the state-of-the-art for ocular MAM/PBPK software through a
combination of expanding the existing knowledge base, development and implementation of enhanced
physiological models for human and animal eyes in the existing Ocular Compartmental Absorption and
Transit™ (OCAT™) model within the GastroPlus™ software program, and validation and documentation
of the resulting software for use by others. By basing the final software program on the well-established and
validated OCAT model, which is in use in the pharmaceutical industry today, we will be able to focus
project resources entirely on advancing the capabilities of the model rather than having to develop new
code for the core program and its many support capabilities (e.g., integration, plotting, Parameter
Sensitivity Analysis, Population Simulations, and drug-drug interactions).
Throughout the effort, we will maintain close contact with the FDA program manager and the Consortium
for Ocular Simulation and Modeling (COSM) that we propose to form with our collaboration partners and
the FDA to ensure the project team focuses on software developments and new experimental work that will
result in developing the optimum software capabilities for ocular dosage form development and
comparison, within the scope of the project.